Organization (Hospital)
Harvard Pilgrim Health Care
ClinicalTrials.gov lists Harvard Pilgrim Health Care as lead sponsor of 35 trials. It has 1 active development program and 2 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 2.8 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Harvard Pilgrim Health Care: 35 lead-sponsored trials and 1 legal-entity registration.
Disease areas (47)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Obesity | 12 |
| Diabetes Mellitus | 7 |
| Asthma | 6 |
| Breast Neoplasms | 4 |
| Alzheimer Disease | 3 |
Showing 5 of 47 disease areas.
Trials by start year as sponsor or collaborator (24)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2025 | 2 |
| 2024 | 4 |
| 2023 | 4 |
| 2022 | 4 |
| 2021 | 1 |
| 2020 | 2 |
| 2019 | 2 |
| 2018 | 5 |
| 2017 | 5 |
| 2016 | 4 |
Showing 10 of 24 years.
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (1)
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Routine Care | Urinary Tract Infections | Not reported | 1 |
Approved assets (2)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Arm 1. Routine Care (Mupirocin/CHG) | 3 |
| Arm 2. Iodophor/CHG Decolonization | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 71% hit target (n=14) | 35% on time (n=17) |
Journals published in (93)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| JAMA | 11 |
| The American journal of clinical nutrition | 11 |
| Medical care | 6 |
| Pediatrics | 6 |
| The Journal of nutrition | 6 |
Showing 5 of 93 journals.
Financing and grant events (182)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2026-05-19 | NIH grant | 1,192,939 | Reporter |
| 2025-09-29 | NIH grant | 570,137 | Reporter |
| 2025-09-22 | NIH grant | 1,511,779 | Reporter |
| 2025-09-03 | NIH grant | 711,115 | Reporter |
| 2025-09-02 | NIH grant | 402,803 | Reporter |
Showing 5 of 182 events.
Organization relationships (15)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Government of the United States of America | Co sponsors trial with | 4 |
| HealthCore, Inc. | Co sponsors trial with | 3 |
| University of Massachusetts, Worcester | Co sponsors trial with | 2 |
| Beth Israel Deaconess Medical Center | Co sponsors trial with | 1 |
| Ochin | Co sponsors trial with | 1 |
Showing 5 of 15 relationships.
Latest dated events (243)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-05-19 | NIH grant | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2025-09-29 | NIH grant | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2025-09-22 | NIH grant | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2025-09-03 | NIH grant | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2025-09-02 | NIH grant | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
Showing 5 of 243 events.
Biomarker capability evidence (18)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| AIM2 | Trial collaborator | Named in trial inclusion criteria |
| TCFL5 | Trial sponsor | Named in trial inclusion criteria |
| TNF | Trial collaborator | Named in trial inclusion criteria |
| TNFRSF1B | Trial collaborator | Named in trial inclusion criteria |
| DPP4 | Trial collaborator | Named in trial exclusion criteria |
Showing 5 of 18 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, us granted patents, sec-reported annual financials, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.